Coagulation, anticoagulation and pancreatic carcinoma

An increase in coagulation in patients with pancreatic carcinoma has long been documented. In this Review, we present what is known about the pathophysiology of increased coagulation in cancer and how it applies to pancreatic carcinoma. The relationship between the activation of coagulation or sympt...

Full description

Saved in:
Bibliographic Details
Main Authors: Nakchbandi, Inaam (Author) , Löhr, J.-Matthias (Author)
Format: Article (Journal)
Language:English
Published: 1 July 2008
In: Nature Clinical Practice. Gastroenterology & Hepatology
Year: 2008, Volume: 5, Issue: 8, Pages: 445-455
ISSN:1743-4386
DOI:10.1038/ncpgasthep1184
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/ncpgasthep1184
Get full text
Author Notes:Inaam A. Nakchbandi and J.-Matthias Löhr
Description
Summary:An increase in coagulation in patients with pancreatic carcinoma has long been documented. In this Review, we present what is known about the pathophysiology of increased coagulation in cancer and how it applies to pancreatic carcinoma. The relationship between the activation of coagulation or symptomatic thromboembolic disease and the development of pancreatic carcinoma is explored. Data on the relationship between thromboembolic disease and the behavior of pancreatic cancer before, during or after a diagnosis is made are also reviewed. Finally, the rationale and evidence for the use of oral anticoagulants or heparin in patients with pancreatic carcinoma is presented. This Review is a critical appraisal of what is known, and when the evidence is acceptable, on the subject of thromboembolism, anticoagulation, and treatment with anticoagulants in patients with pancreatic carcinoma.
Item Description:Gesehen am 28.06.2021
Physical Description:Online Resource
ISSN:1743-4386
DOI:10.1038/ncpgasthep1184